BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research report released on Wednesday.
Several other research firms also recently commented on ASND. Bank of America raised their price objective on Ascendis Pharma A/S from $36.00 to $46.00 in a report on Thursday, September 28th. Leerink Swann reaffirmed a hold rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. HC Wainwright reaffirmed a buy rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. Credit Suisse Group reaffirmed an outperform rating and set a $50.00 target price (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Wedbush reaffirmed an outperform rating and set a $10.71 target price (down previously from $65.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $36.45.
Ascendis Pharma A/S (NASDAQ ASND) opened at $40.09 on Wednesday. The company has a market capitalization of $1,460.00 and a price-to-earnings ratio of -10.25. Ascendis Pharma A/S has a fifty-two week low of $19.21 and a fifty-two week high of $42.00.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
What are top analysts saying about Ascendis Pharma A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ascendis Pharma A/S and related companies.